The efficacy of trametinib

Administration of 1 mg and 2 mg trametinib tablets to patients with BRAF V600 mutation-positive melanoma resulted in dose-dependent changes in tumor biomarkers, including inhibition of phosphorylated ERK, inhibition of Ki67 (a marker of cell proliferation), and an increase in p27 (a marker of apoptosis). After oral administration, trametinib is rapidly and easily absorbed.

In a dedicated study, the rate-corrected QT (QTc) prolonging potential of trametinib was evaluated in 32 patients who received placebo on day 1, 2 mg trametinib tablets once daily on days 2-14, and then 3 mg trametinib tablets on day 15. No clinically relevant QTc prolongation was detected in the study. In clinical trials of patients receiving trametinib and dabrafenib, 0.8% of patients experienced a QTc prolongation of >500 ms, and 3.8% of patients experienced a QTc increase of >60 ms from baseline.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).